Literature DB >> 27662840

NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines.

Jinhuai Hu1, Yong Huang2, Yuanhua Wu2, Fengjun Liu3, Dong Sun4, Kexin Wang4, Hui Qu4.   

Abstract

In this study, we examined the roles of neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene in regulating in vitro proliferation and invasion in human gastric cancer. Gene expression of NTRK2 was compared between non-carcinoma gastric epithelial cells and gastric cancer (GC) cells by quantitative RT-PCR (qRT-PCR). NTRK2 was either downregulated or upregulated in MKN-28 and SNU-719 cells. The effect of NTRK2 downregulation or upregulation on GC in vitro development was analyzed by qRT-PCR, western blot, proliferation assay, and invasion assay, respectively. The upstream regulator of NTRK2, microRNA-22 (miR-22), was evaluated by dual-luciferase assay. MiR-22 was then upregulated in MKN-28 and SNU-719 cells to examine its regulation on NTRK2 and its encoded protein, tyrosine kinase receptor B (TrkB). In miR-22-upregulated MKN-28 and SNU-719 cells, NTRK2 was further overexpressed to evaluate functional interaction between miR-22 and NTRK2 in GC. NTRK2 was aberrantly upregulated in GC cell lines than in normal gastric cells. In MKN-28 and SNU-719 cells, NTRK2 downregulation inhibited whereas NTRK2 upregulation promoted GC proliferation and invasion in vitro. MiR-22 was verified to be an inverse upstream regulator of NTRK2. In miR-22-upregulated MKN-28 and SNU-719 cells, NTRK2 overexpression partially reversed the miR-22-induced inhibition on cancer proliferation and invasion. NTRK2 is an oncogene and reversely associated with miR-22 in regulating in vitro cancer development in GC.

Entities:  

Keywords:  Gastric cancer; Migration; NTRK2; Proliferation; TrkB; miR-22

Mesh:

Substances:

Year:  2016        PMID: 27662840     DOI: 10.1007/s13277-016-5337-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells.

Authors:  Hiroyuki Fujikawa; Koji Tanaka; Yuji Toiyama; Susumu Saigusa; Yasuhiro Inoue; Keiichi Uchida; Masato Kusunoki
Journal:  J Gastroenterol       Date:  2012-02-24       Impact factor: 7.527

2.  Resistance to chemotherapy mediated by TrkB in neuroblastomas.

Authors:  Ruth Ho; Angelika Eggert; Tomoro Hishiki; Jane E Minturn; Naohiko Ikegaki; Patricia Foster; Anna Marie Camoratto; Audrey E Evans; Garrett M Brodeur
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

3.  Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death.

Authors:  Zhijie Li; Jerry Jaboin; Phillip A Dennis; Carol J Thiele
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

4.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  Annual report on status of cancer in China, 2011.

Authors:  Wanqing Chen; Rongshou Zheng; Hongmei Zeng; Siwei Zhang; Jie He
Journal:  Chin J Cancer Res       Date:  2015-02       Impact factor: 5.087

6.  Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer.

Authors:  Kyoko Okamura; Taishi Harada; Shuo Wang; Kayo Ijichi; Kazuto Furuyama; Takaomi Koga; Tatsuro Okamoto; Koichi Takayama; Tokujiro Yano; Yoichi Nakanishi
Journal:  Lung Cancer       Date:  2012-08-18       Impact factor: 5.705

7.  miR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1.

Authors:  Mei-Mei Guo; Li-Hua Hu; Yong-Qiang Wang; Peng Chen; Jian-Guo Huang; Ning Lu; Jiang-Hong He; Cheng-Gong Liao
Journal:  Med Oncol       Date:  2013-03-26       Impact factor: 3.064

Review 8.  A systematic review of microRNA expression profiling studies in human gastric cancer.

Authors:  Sirjana Shrestha; Sheng-Da Hsu; Wei-Yun Huang; Hsi-Yuan Huang; WenLiang Chen; Shun-Long Weng; Hsien-Da Huang
Journal:  Cancer Med       Date:  2014-06-05       Impact factor: 4.452

9.  Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer.

Authors:  Y Okugawa; K Tanaka; Y Inoue; M Kawamura; A Kawamoto; J Hiro; S Saigusa; Y Toiyama; M Ohi; K Uchida; Y Mohri; M Kusunoki
Journal:  Br J Cancer       Date:  2012-11-22       Impact factor: 7.640

Review 10.  Free intraperitoneal tumor cells and outcome in gastric cancer patients: a systematic review and meta-analysis.

Authors:  Mathieu Pecqueux; Johannes Fritzmann; Mariam Adamu; Kristian Thorlund; Christoph Kahlert; Christoph Reißfelder; Jürgen Weitz; Nuh N Rahbari
Journal:  Oncotarget       Date:  2015-11-03
View more
  2 in total

1.  CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630.

Authors:  Yan Zhang; Hao Liu; Wende Li; Jiang Yu; Jin Li; Zhiyong Shen; Gentai Ye; Xiaolong Qi; Guoxin Li
Journal:  Aging (Albany NY)       Date:  2017-06-27       Impact factor: 5.682

2.  Comprehensive Network Analysis Identified SIRT7, NTRK2, and CHI3L1 as New Potential Markers for Intervertebral Disc Degeneration.

Authors:  Haoxi Li; Wenhao Li; Li Zhang; Jicheng He; Lin Tang; Zhuhai Li; Feng Chen; Qie Fan; Jianxun Wei
Journal:  J Oncol       Date:  2022-02-12       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.